Toronto-based Cutting Class Studios has partnered with executive producers Robert Salomon and Brian Knappmiller for a multi-part documentary on the CIA-run MKUltra experiments, and the impact they had ...

BlackRock’s spot Bitcoin exchange-traded fund IBIT, has emerged as a notable outlier on the 2025 ETF flow leaderboard, ranking sixth by year-to-date inflows despite posting a negative return for the ...

Learn how to use advanced techniques like short-circuiting, parallel execution, virtual threads, and stream gatherers to maximize Java stream performance. My recent Java Stream API tutorial introduced ...

Oracle Corp. said final negotiations on an equity deal for a data center project in Michigan are “on schedule” and doesn’t include Blue Owl Capital, a firm that has helped finance massive data center ...

One of the promises underwriting the AI boom is that software will be able to use computers on our behalf. At the low end, this looks like the “deep research” tools AI firms have already released that ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

In the first months after lawmakers removed a family income eligibility requirement for New Hampshire’s education freedom account program, nearly all of the students who enrolled for the first time ...

InSight Crime’s internship program offers the opportunity to work for the leading source of news and analysis on organized crime in Latin America and the Caribbean. Our internship program in the Data ...

I start with the Dividend Triangle—multi-year trends in revenue, EPS, and dividends—to find steady compounders across cycles. Working capital timing, inventory builds, and one-offs can make great ...

After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...

Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability data that fell short of expectations as well as evidence the ...